Advaxis Inc. in brief
Advaxis Inc. is an unlisted company in the Biotechnology industry, based in Monmouth Junction, New Jersey, USA. It was founded in 2002. In the year to December 2023 it had sales of $0 M and a net loss of $48 M.
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Advaxis Inc.
Advaxis Immunotherapies Inc. was an American company that focused on the discovery, development, and commercialization of immunotherapies based on a genetically engineered platform based on Listeria monocytogenes (aka Lm). The company merged with Ayala Pharmaceuticals, with the newly formed company beginning operations under the name Ayala Pharmaceuticals in January 2023.
The Lm-based platform on which the company's products were based involves the use of an attenuated Lm, which secretes an antigen/adjuvant fusion protein and stimulates a patient's immune system (specifically their T cells) to mount an immune response to the secreted antigen. If the antigen is specifically found on cancerous cells, the result is an immune response targeting and eliminating the cancer. Treatments developed using this paradigm are referred to as Lm-LLO immunotherapies.
The company had over fifteen constructs in various stages of development, both directly and through strategic collaborations with centers, such as the National Cancer Institute, Cancer Research UK, the Wistar Institute, the University of Pennsylvania, and the Department of Homeland Security,among others. The company also had a veterinary medicine program that was evaluating an Lm-LLO-based immunotherapy in a Phase 1 study in canine osteosarcoma.
From Wikipedia: read the full article · text available under CC BY-SA 4.0
Advaxis Inc. timeline
- 1999
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2002
- 🏁· approximateFounded
- 2005
- ✎Renamed Advaxis, Inc.Formerly Great Expectations & Associates Inc.
- 2023
- ✎Renamed Ayala Pharmaceuticals, Inc.Formerly Advaxis, Inc..
Events of Advaxis Inc. from SEC EDGAR and Wikidata. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
More about Advaxis Inc.
- Acquisitions and changes
- Delisted: it ended its SEC registration (Form 15) on 9 May 2024.
Market cap history
World rank over time
Rank in USA: #5,301 (Jan 2022) · #5,891 (Dec 2022) · #5,575 (Jul 2023)
Key ratios
- P/E ratio (TTM)
- n/m (loss)
- Price / sales (TTM)
- —
- Price / book
- —
- Free cash flow yield
- —
- Net margin (TTM)
- -480700.0%
- Operating margin
- -362700.0%
- Return on equity
- —
- Liabilities / assets
- 247.3%
- Revenue growth
- -98.6%
- R&D / revenue
- 240800.0%
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2023 | $0M | -98.6% | $-36M | $-48M | -480700.0% |
| Dec 2022 | $1M | -78.7% | $-38M | $-38M | -5508.7% |
| Oct 2021 | $3M | +1196.0% | $-19M | $-18M | -551.2% |
| Oct 2020 | $0M | -98.8% | $-26M | $-26M | -10588.0% |
| Oct 2019 | $21M | +244.6% | $-18M | $-17M | -79.5% |
| Oct 2018 | $6M | -49.6% | $-70M | $-67M | -1097.7% |
| Oct 2017 | $12M | +201.5% | $-98M | $-93M | -776.7% |
| Oct 2016 | $4M | — | $-76M | $-74M | -1843.6% |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2023 | $-29M | — | — | $-7.99 | — |
| Dec 2022 | $-35M | — | — | $-13.13 | — |
| Oct 2021 | $-15M | — | — | $-0.14 | — |
| Oct 2020 | $-22M | — | — | $-0.43 | — |
| Oct 2019 | $-36M | $0M | $-36M | $-1.09 | — |
| Oct 2018 | $-62M | $1M | $-64M | $-19.36 | — |
| Oct 2017 | $-77M | $3M | $-80M | $-2.31 | — |
| Oct 2016 | $-9M | $3M | $-12M | $-2.08 | — |
Quarterly results
Latest quarter to Dec 2023: revenue —, net income $-25M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Dec 2023.
SEC filings
- Apr 26, 202410-K/AAnnual report (amended) · period to Dec 2023
- Apr 19, 20248-K/ACurrent report (amended)
- Apr 16, 202410-KAnnual report · period to Dec 2023
- Apr 3, 20248-KCurrent reportDirectors or officers changed
- Mar 29, 20248-KCurrent reportAcquisition or disposal completed · Unregistered share sale · Regulation FD disclosure
- Mar 5, 20248-KCurrent reportMaterial agreement · New financial obligation
- Feb 23, 20248-KCurrent reportDirectors or officers changed
- Feb 9, 20248-KCurrent reportUnregistered share sale · Shareholder vote
- Feb 6, 20248-KCurrent reportMaterial agreement · Directors or officers changed · Regulation FD disclosure
- Jan 3, 20248-K/ACurrent report (amended)
- Nov 20, 202310-QQuarterly report · period to Sep 2023
- Oct 20, 20238-KCurrent reportAcquisition or disposal completed · Unregistered share sale · Directors or officers changed
Official filings of Advaxis Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- $0 M
- Operating income
- $-36 M
- Net income
- $-48 M
For year ending December-2023 · source: SEC filing
Balance sheet
- Total assets
- $17 M
- Total liabilities
- $41 M
- Total equity
- $-24 M
As of December-2023
Insider trading at Advaxis Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Israel Biotech Fund GP Partners, L.P.Director, 10% owner | Option exerciseindirect | +1.93 M | $0.400 | $770 K | 11.04 M | Form 4 |
| filed | Israel Biotech Fund GP Partners, L.P.Director, 10% owner | Option exerciseindirect | +4.24 M | $0.400 | $1.7 M | 18.36 M | Form 4 |
| filed | Israel Biotech Fund GP Partners, L.P.Director, 10% owner | Option exerciseindirect | +3.89 M | $0.400 | $1.6 M | 14.93 M | Form 4 |
| filed | Israel Biotech Fund GP Partners, L.P.Director, 10% owner | Option exerciseindirect | +1.30 M | $0.400 | $518 K | 19.66 M | Form 4 |
| filed | Israel Biotech Fund GP Partners, L.P.Director, 10% owner | Option exerciseindirect | +8.44 M | $0.400 | $3.4 M | 23.37 M | Form 4 |
| filed | Israel Biotech Fund GP Partners, L.P.Director, 10% owner | Shares withheld for taxindirect | -2.71 M | $1.250 | $3.4 M | 20.66 M | Form 4 |
| filed | Israel Biotech Fund GP Partners, L.P.Director, 10% owner | Option exerciseindirect | +8.06 M | $0.400 | $3.2 M | 27.72 M | Form 4 |
| filed | Israel Biotech Fund GP Partners, L.P.Director, 10% owner | Shares withheld for taxindirect | -2.59 M | $1.250 | $3.2 M | 25.13 M | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: Advaxis Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Fails to deliver
- : 5 shares at $0.03
- : 5 shares at $0.03
- : 5 shares at $0.04
- : 44 shares at $0.03
- : 44 shares at $0.03
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Advaxis Inc. scorecard#
Passes 1 of the 8 checks that could be worked out. Fiscal year 2023.
Valuationnot known
- –P/E below its peers' medianNo market cap.
- –Price to book below its peers' medianNo market cap.
- –Price to sales below its peers' medianNo market cap.
- –Free cash flow yield above 5%No market cap.
- –Earnings yield above the 10-year Treasury yieldNo market cap.
- –The price assumes slower growth than the last three years'No market cap.
Growth1 of 3
- –Revenue grew in the newest yearRevenue of the year before is not on file.
- –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
- –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
- ✗Earnings per share grew in the newest year-7.99 vs -13.13Diluted EPS -7.99 in fiscal 2023 against -13.13 the year before (report's currency).
- ✓Net income higher than five years earlier-$48 M-$48 M in fiscal 2023 against -$67 M in 2018.
- ✗Revenue rose in at least four of the last five years2 of 5Revenue rose in 2 of the five years to fiscal 2023.
Profitability0 of 2
- ✗Profitable in the newest year-$48 MNet income -$48 M in fiscal 2023.
- ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2023.
- –Operating margin above its peers' medianNo operating margin on file.
- –Return on equity above 15%No return on equity (equity missing or negative).
- –Return on invested capital above 10%No return on invested capital on file.
- –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
Financial health0 of 2
- ✗Short-term assets cover short-term liabilities0.3×Current ratio 0.30 at the end of fiscal 2023.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2023.
- –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
Shareholder returns0 of 1
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✗Share count up no more than 2% in a year107.9%Diluted shares up 107.9% in fiscal 2023.
- –Dividends and buybacks above 3% of the market valueNo market cap.
- –Free cash flow covers dividends and buybacksCash from operations or capital spending is not on file.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Advaxis Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Oct 31, 2021 | FY 2020to Oct 31, 2020 | FY 2019to Oct 31, 2019 | FY 2018to Oct 31, 2018 | FY 2017to Oct 31, 2017 | FY 2016to Oct 31, 2016 | FY 2015to Oct 31, 2015 | FY 2014to Oct 31, 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||
| Revenue | 0.0−98.1%100% | 0.7−78.6%100% | 3.2+1181%100% | 0.3−98.8%100% | 21+244%100% | 6.1−49.6%100% | 12r12+201%100% | 4.0—100% | — | 1.0—100% | |
| Cost of revenue | 0.0−97.8%100% | 0.6—87.0% | — | — | — | — | — | — | — | — | |
| Gross profit | — | 0.1—13.0% | — | — | — | — | — | — | — | — | |
| Research and development | 24−13.5%185238% | 28+164%4025% | 11−32.3%326% | 16−41.5%6171% | 27−53.2%128% | 57−19.2%940% | 71r72+44.6%586% | 49+99.4%1221% | 24r24+176%— | 8.9r8.7—886% | |
| General and administrative | 12+25.1%93731% | 9.7−15.0%1408% | 11+3.4%354% | 11−8.9%4383% | 12−37.5%58.3% | 19−51.3%321% | 40r39+26.0%332% | 32+30.8%794% | 24r24+108%— | 12r12—1168% | |
| Operating expenses | — | — | 22−17.5%680% | 27−31.3%10554% | 39−49.2%186% | 76−30.8%1261% | 110r111+37.3%918% | 80+65.3%2015% | 49r49+137%— | 21—2054% | |
| Operating income | −36—−278969% | −38—−5420% | −19—−580% | −26—−10454% | −18—−86.1% | −70—−1161% | −98r−99—−818% | −76—−1915% | −49r−49—— | −20—−1954% | |
| Interest expense and finance costs | — | — | — | — | — | — | — | — | — | 0.0—0.5% | |
| Other non-operating income (expense) | −16−21341%−120908% | 0.1—10.7% | −0.0—−0.0% | — | −0.0—−0.0% | −0.1—−1.0% | −0.1r−0.0—−0.7% | −0.0—−0.0% | −0.0r−0.0−767%— | 0.0r0.0—0.1% | |
| Income before tax | −52—−399877% | −37—−5409% | −18—−550% | −26—−10442% | −17—−79.3% | −66—−1096% | −98r−98—−813% | −76—−1905% | −49—— | −19—−1888% | |
| Income tax | −3.9−770%−30092% | 0.6+1068%84.4% | 0.10.0%1.5% | 0.10.0%19.8% | 0.10.0%0.2% | 0.1—0.8% | −4.4r−4.4—−36.6% | −2.5—−63.5% | −1.6—— | −2.4—−236% | |
| Net income attributable to shareholders | −48—−369785% | −38—−5493% | −18—−551% | −26—−10462% | −17—−79.5% | −67—−1097% | −93r−93—−777% | −74—−1841% | −47—— | −17—−1653% | |
| Earnings per share, basic | -7.99—— | -13.13—— | -11.07r-0.14—— | -0.43—— | -1.09—— | -19.36r-1.29—— | -2.31—— | -2.08—— | -1.68—— | -0.97—— | |
| Earnings per share, diluted | -7.99—— | -13.13—— | -0.14—— | -0.43—— | -1.09—— | -19.36r-1.29—— | -2.31—— | -2.08—— | -1.68—— | -0.97—— | |
| Shares, weighted average (basic) | 6.0+108%— | 2.9+79.4%— | 1.6—— | — | — | — | — | — | — | — | |
| Shares, weighted average (diluted) | 6.0+108%— | 2.9−97.8%— | 129+112%— | 61+301%— | 15+343%— | 3.4r52−91.5%— | 41+14.5%— | 35+26.3%— | 28+63.8%— | 17—— | |
| Balance sheet | |||||||||||
| Cash and cash equivalents | 4.9+103%29.4% | 2.4−94.2%31.0% | 42+65.3%89.0% | 25−22.2%65.4% | 32−26.7%71.5% | 44+84.7%70.9% | 24r24−78.8%25.5% | 113r113+69.4%66.7% | 67+278%55.7% | 18—75.3% | |
| Short-term investments | — | 0.1—1.4% | — | — | — | — | 46r46—49.5% | — | — | — | |
| Receivables | — | 0.2—3.0% | — | — | — | 1.7—2.7% | — | — | — | — | |
| Other current assets | 0.2+3340%1.0% | 0.0r0.4−99.7%0.1% | 1.6+89.9%3.5% | 0.9−39.6%2.2% | 1.4−11.0%3.2% | 1.6r3.3−44.8%2.6% | 2.9r2.9+5361%3.1% | 0.1r0.1+254%0.0% | 0.0+84.7%0.0% | 0.0—0.0% | |
| Current assets | 7.5+136%45.4% | 3.2−92.6%41.0% | 43+55.3%92.5% | 28−23.0%72.3% | 36−28.4%79.9% | 50−37.9%81.0% | 81r81−49.2%86.8% | 160+39.0%94.6% | 115+461%96.2% | 20—87.7% | |
| Property, plant and equipment | 0.5−43.8%3.3% | 1.0+714%12.4% | 0.1−95.1%0.3% | 2.4−45.0%6.2% | 4.4−34.9%9.6% | 6.7−6.0%10.7% | 7.1r7.1+62.0%7.6% | 4.4+304%2.6% | 1.1+1305%0.9% | 0.1—0.3% | |
| Right-of-use (leased) assets | 0.1−93.0%0.6% | 1.5+3555%18.8% | 0.0−99.2%0.1% | 4.8−8.7%12.6% | 5.3—11.7% | — | — | — | — | — | |
| Goodwill | 4.5—27.1% | — | — | — | — | — | — | — | — | — | |
| Other intangible assets | 3.9—23.5% | — | 3.4+2.9%7.2% | 3.3−28.7%8.5% | 4.6−5.4%10.1% | 4.8−0.4%7.8% | 4.9r4.9+12.2%5.2% | 4.3+29.0%2.6% | 3.4+21.2%2.8% | 2.8—11.8% | |
| Non-current assets | 9.1+97.6%54.6% | 4.6—59.0% | — | — | — | — | — | — | — | — | |
| Total assets | 17+113%100% | 7.8−83.4%100% | 47+21.4%100% | 39−14.9%100% | 45−27.3%100% | 62−33.5%100% | 94r94−44.6%100% | 169+41.3%100% | 120+412%100% | 23—100% | |
| Accounts payable | 6.1+48.9%36.6% | 4.1+4590%52.5% | 0.1−78.8%0.2% | 0.4−58.0%1.1% | 1.0−82.7%2.2% | 5.6+10.3%9.1% | 5.1r5.1+198%5.5% | 1.7+147%1.0% | 0.7−50.7%0.6% | 1.4—6.0% | |
| Current liabilities | 25+303%151% | 6.2r7.5−21.3%79.8% | 7.9+139%16.8% | 3.3−27.2%8.5% | 4.5−80.2%10.0% | 23+9.6%36.7% | 21r21−24.7%22.3% | 28+607%16.4% | 3.9+44.3%3.3% | 2.7—11.6% | |
| Lease liabilities (non-current) | 0.0−99.3%0.1% | 1.3+11000%17.1% | 0.0−99.8%0.0% | 5.1—13.1% | — | — | — | — | — | — | |
| Non-current liabilities | 16+499%96.4% | 2.7r1.3—34.3% | — | — | — | — | — | — | — | — | |
| Total liabilities | — | — | 7.9−5.4%16.9% | 8.3+45.8%21.7% | 5.7−85.0%12.7% | 38−3.0%61.4% | 39r39−20.8%42.1% | 50+1141%29.4% | 4.0+45.8%3.4% | 2.7—11.8% | |
| Retained earnings | −197—−1190% | −149—−1920% | −429—−916% | −411—−1066% | −384—−849% | −368—−590% | −301r−301—−322% | −208—−123% | −134—−112% | −87—−372% | |
| Shareholders' equity | −24—−147% | −1.1−103%−14.1% | 39+28.9%83.1% | 30−23.7%78.3% | 40+64.4%87.3% | 24−55.7%38.6% | 54r54−54.5%57.9% | 119r119+3.2%70.6% | 116+460%96.6% | 21—88.2% | |
| Total liabilities and equity | 17+113%100% | 7.8−83.4%100% | 47+21.4%100% | 39−14.9%100% | 45−27.3%100% | 62−33.5%100% | 94r94−44.6%100% | 169+41.3%100% | 120+412%100% | 23—100% | |
| Shares outstanding | 12+349%— | 2.6r2.7+44.9%— | 1.8r146−97.7%— | 78+55.5%— | 50+983%— | 4.6r70−88.8%— | 41+2.9%— | 40r40+19.3%— | 34+71.0%— | 20—— | |
| Cash-flow statement | |||||||||||
| Depreciation and amortization | 0.4+128%2838% | 0.2—23.4% | — | — | — | — | — | — | — | 0.2—17.6% | |
| Share-based compensation | 1.2−45.5%9408% | 2.2+296%324% | 0.6−36.5%17.5% | 0.9−55.5%352% | 2.0−71.3%9.6% | 7.0−74.9%115% | 28r28+18.6%231% | 23+9.5%588% | 21+299%— | 5.4r4.4—537% | |
| Cash from operating activities | −29—−226808% | −35—−4987% | −15—−477% | −22—−8672% | −36—−173% | −62—−1025% | −77r−77—−639% | −9.1r−9.1—−229% | −24r−24—— | −16r−17—−1608% | |
| Capital expenditure | — | — | — | — | −0.1—−0.3% | −1.4—−23.5% | −3.4r−3.4—−28.7% | −3.2—−80.7% | −1.0—— | −0.0—−2.5% | |
| Intangible assets bought | — | — | −0.5—−14.2% | −0.7—−296% | −1.2—−5.9% | −1.4—−23.4% | −1.2r−1.2—−9.7% | −1.2—−30.7% | −0.8—— | −0.4—−41.5% | |
| Cash from investing activities | 5.9—45738% | −0.0—−0.3% | −0.0—−0.3% | −0.7—−296% | −1.2−103%−5.7% | 44r43—719% | −12r−12−900%−104% | 1.6—39.0% | −47—— | −0.4—−44.0% | |
| Shares issued | — | 0.5−98.2%74.0% | 28+81.4%868% | 15−36.7%6125% | 24−37.6%117% | 39+5884%647% | 0.7−98.8%5.5% | 53−55.6%1330% | 120+721%— | 15—1458% | |
| Cash from financing activities | 26—200008% | −0.1−100%−14.9% | 32+106%984% | 16−36.9%6128% | 25−37.3%118% | 39+8669%646% | 0.4r0.5−99.2%3.7% | 54r54−55.4%1346% | 121r121+788%— | 14r15—1358% | |
| Exchange-rate effect on cash | 0.0—200% | — | — | — | — | — | — | — | — | — | |
| Change in cash | 2.5—19138% | −35−311%−5002% | 16—507% | −7.2—−2840% | −13−162%−61.1% | 21—340% | — | — | — | — | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Dec 31, 2023 | Q4 FY2023to Dec 31, 2023 | Q3 FY2023to Sep 30, 2023 | Q2 FY2023to Jun 30, 2023 | Q1 FY2023to Mar 31, 2023 | Q4 FY2021to Oct 31, 2021 | Q3 FY2021to Jul 31, 2021 | Q2 FY2021to Apr 30, 2021 | Q1 FY2021to Jan 31, 2021 | Q4 FY2020to Oct 31, 2020 | Q3 FY2020to Jul 31, 2020 | Q2 FY2020to Apr 30, 2020 | Q1 FY2020to Jan 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Revenue | 0.0−99.6%100% | 0*—— | 0*—— | 0.0—100% | 0.0—100% | 0*—— | 0.3—100% | 1.4+450%100% | 1.6+53733%100% | 0*—— | 0*—— | 0.3—100% | 0.0—100% | |
| Cost of revenue | 0.0—100% | 0*—— | 0*—— | 0.0—100% | 0.0—100% | — | — | — | — | — | — | — | — | |
| Research and development | 24+128%185238% | 5.4*—— | 5.7—— | 5.7—63589% | 7.3—181625% | 1.9*−42.3%— | 1.7−50.8%681% | 4.3+10.8%316% | 2.6−47.1%159% | 3.4*—— | 3.5—— | 3.9—1569% | 4.9—161967% | |
| General and administrative | 12+6.3%93731% | 3.4*—— | 1.4—— | 2.8—30700% | 4.6—115100% | 2.4*−19.9%— | 2.7+12.3%1071% | 3.4+26.5%244% | 3.0−0.7%186% | 3.0*—— | 2.4—— | 2.6—1060% | 3.0—101000% | |
| Operating expenses | — | — | — | — | — | 4.4*−31.7%— | 4.4−25.0%1752% | 7.7+17.1%560% | 5.6−29.3%345% | 6.4*—— | 5.8—— | 6.6—2628% | 7.9—262967% | |
| Operating income | −36—−278969% | −8.8*—— | −7.1—— | −8.5—−94289% | −12—−296725% | −4.4*—— | −4.1—−1652% | −6.3—−460% | −4.0—−245% | −6.4*—— | −5.8—— | −6.3—−2528% | −7.9—−262867% | |
| Other non-operating income (expense) | — | −16*—— | −0.1—— | −0.1—−956% | — | −0.2*—— | 0*—0.0% | 0.2—15.8% | 0.0—0.7% | — | −0.0—— | −0.0—−0.4% | — | |
| Income before tax | −52—−399877% | −25*—— | −7.3—— | −8.6—−95244% | −12—−289200% | −5.4*—— | −3.3—−1314% | −5.1—−371% | −4.0—−246% | −6.5*—— | −5.8—— | −6.3—−2509% | −7.9—−261900% | |
| Income tax | −3.9—−30092% | 0.1*—— | 0.1—— | 0.1—1411% | −4.2—−105175% | 0*—— | 0.1—20.0% | — | — | 0*—— | 0*—— | 0.1—20.0% | — | |
| Net income attributable to shareholders | −48—−369785% | −25*—— | −7.3—— | −8.7—−96656% | −7.4—−184025% | −5.4*—— | −3.3—−1334% | −5.1—−371% | −4.0—−246% | −6.5*—— | −5.8—— | −6.3—−2529% | −7.9—−261900% | |
| Earnings per share, basic | — | — | -1.53—— | -1.82—— | -1.67—— | — | -1.83r-0.02—— | -3.32r-0.04—— | -0.05—— | — | -0.09—— | -0.10—— | -0.15—— | |
| Earnings per share, diluted | — | — | -1.53—— | -1.82—— | — | — | -0.02—— | -0.04—— | -0.05—— | — | -0.09—— | -0.10—— | -0.15—— | |
| Shares, weighted average (basic) | — | — | 4.8—— | 4.8—— | 4.4—— | — | 1.8—— | 1.5−97.5%— | — | — | — | 61—— | 52—— | |
| Shares, weighted average (diluted) | — | — | 4.8—— | 4.8—— | — | — | 146+136%— | 123+103%— | 84+62.2%— | — | 62—— | 61—— | 52—— | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 4.9—29.4% | 4.9—29.4% | 2.1—30.4% | 7.1—58.3% | 17—80.2% | 42+65.3%89.0% | 45+89.8%88.7% | 48+70.5%86.3% | 33−2.5%72.5% | 25—65.4% | 24—59.6% | 28—62.4% | 34—66.5% | |
| Short-term investments | — | — | 0.1—1.5% | 0.1—0.9% | 0.1—0.5% | — | — | — | — | — | — | — | — | |
| Receivables | — | — | — | — | 0.0—0.0% | — | — | 1.4—2.5% | — | — | — | — | — | |
| Other current assets | 0.2—1.0% | 0.2—1.0% | 2.3—33.3% | 2.4—19.5% | 1.3—6.2% | 1.6+89.9%3.5% | 1.1−11.9%2.2% | 1.3−27.0%2.3% | 0.6−37.0%1.3% | 0.9—2.2% | 1.3—3.2% | 1.8—3.9% | 1.0—1.9% | |
| Current assets | 7.5—45.4% | 7.5—45.4% | 4.6—65.2% | 9.6—78.6% | 18—87.0% | 43+55.3%92.5% | 47+73.8%93.0% | 52+64.0%93.4% | 36−4.4%77.3% | 28—72.3% | 27—68.2% | 32—70.3% | 37—72.4% | |
| Property, plant and equipment | 0.5—3.3% | 0.5—3.3% | 0.8—12.1% | 0.9—7.3% | 1.0—4.5% | 0.1−95.1%0.3% | 0.3−92.4%0.5% | 0.3−91.4%0.6% | 2.2−46.9%4.8% | 2.4—6.2% | 3.7—9.2% | 3.9—8.6% | 4.1—8.0% | |
| Right-of-use (leased) assets | 0.1—0.6% | 0.1—0.6% | 1.3—18.3% | 1.4—11.4% | 0.1r1.4—0.3% | 0.0−99.2%0.1% | — | — | 4.6−14.0%10.1% | 4.8—12.6% | 5.0—12.6% | 5.2—11.5% | 5.4—10.5% | |
| Goodwill | 4.5—27.1% | 4.5—27.1% | — | — | — | — | — | — | — | — | — | — | — | |
| Other intangible assets | 3.9—23.5% | 3.9—23.5% | 0.1—1.5% | 0.1—0.9% | 0.1—0.6% | 3.4+2.9%7.2% | 3.3−14.3%6.5% | 3.3−19.9%6.0% | 3.4−24.2%7.4% | 3.3—8.5% | 3.8—9.6% | 4.1—9.2% | 4.5—8.7% | |
| Non-current assets | 9.1—54.6% | 9.1—54.6% | 2.4—34.8% | 2.6—21.4% | 2.7—13.0% | — | — | — | — | — | — | — | — | |
| Total assets | 17—100% | 17—100% | 7.0—100% | 12—100% | 21—100% | 47+21.4%100% | 51+27.5%100% | 56+23.4%100% | 46−10.5%100% | 39—100% | 40—100% | 45—100% | 51—100% | |
| Accounts payable | 6.1—36.6% | 6.1—36.6% | 5.1—72.4% | 4.4—36.4% | 4.1—19.7% | 0.1−78.8%0.2% | 0.5+9.7%0.9% | 1.2−24.4%2.1% | 0.4−10.1%0.9% | 0.4—1.1% | 0.4—1.0% | 1.5—3.4% | 0.4—0.9% | |
| Current liabilities | 25—151% | 25—151% | 8.5—122% | 8.4—69.4% | 9.8—46.8% | 7.9+139%16.8% | 6.7+108%13.2% | 8.2+94.6%14.7% | 3.6−10.8%7.8% | 3.3—8.5% | 3.2—8.1% | 4.2—9.3% | 4.0—7.8% | |
| Lease liabilities (non-current) | 0.0—0.1% | 0.0—0.1% | 0.9—13.4% | 1.0—8.2% | 1.4—6.7% | 0.0−99.8%0.0% | — | — | 4.8−17.2%10.4% | 5.1—13.1% | 5.3—13.3% | 5.5—12.3% | 5.8—11.3% | |
| Non-current liabilities | 16—96.4% | 16—96.4% | 4.7—67.3% | 2.7—22.3% | 1.5—7.1% | — | — | — | — | — | — | — | — | |
| Total liabilities | — | — | — | — | — | 7.9−5.4%16.9% | 6.7−21.1%13.2% | 8.2−15.9%14.7% | 8.4−14.6%18.2% | 8.3—21.7% | 8.6—21.4% | 9.8—21.6% | 9.8—19.1% | |
| Retained earnings | −197—−1190% | −197—−1190% | −173—−2472% | −165—−1360% | −157—−745% | −429—−916% | −423—−829% | −420—−753% | −415—−903% | −411—−1066% | −404—−1010% | −398—−881% | −392—−764% | |
| Shareholders' equity | −24—−147% | −24—−147% | −6.2—−89.4% | 1.0—8.3% | 9.7—46.1% | 39+28.9%83.1% | 44+40.7%86.8% | 48+34.2%85.3% | 38−9.6%81.8% | 30—78.3% | 31—78.6% | 35r35—78.4% | 42r42—80.9% | |
| Total liabilities and equity | 17—100% | 17—100% | 7.0—100% | 12—100% | 21—100% | 47+21.4%100% | 51+27.5%100% | 56+23.4%100% | 46−10.5%100% | 39—100% | 40—100% | 45—100% | 51—100% | |
| Shares outstanding | 12—— | 12—— | 4.8—— | 4.8—— | 4.8—— | 1.8r146−97.7%— | 146+132%— | 146+142%— | 116+92.8%— | 78—— | 63—— | 60—— | 60—— | |
| Cash-flow statement | ||||||||||||||
| Share-based compensation | — | — | 0.1*—— | 0.0*—367% | 1.2—29650% | 0.1*−69.9%— | 0.1−76.5%24.0% | 0.2+2.4%15.6% | 0.2−2.5%14.6% | 0.2*—— | 0.3—— | 0.2—84.0% | 0.2—8067% | |
| Cash from operating activities | −29—−226808% | −7.2*—— | −7.0*—— | −8.6*—−95122% | −6.7—−168525% | −3.7*—— | −2.8*—−1121% | −6.1*—−445% | −2.8—−173% | −3.2*—— | −5.3*—— | −5.7*—−2285% | −7.7—−256933% | |
| Intangible assets bought | — | — | — | — | — | −0.1*—— | −0.1*—−22.0% | −0.1*—−4.2% | −0.2—−13.0% | −0.3*—— | −0.1*—— | −0.1*—−48.0% | −0.2—−7933% | |
| Cash from investing activities | — | — | — | — | — | 0.1*—— | −0.1*—−20.0% | 0.2*—11.3% | −0.2—−13.0% | −0.3*—— | −0.1*—— | −0.1*—−48.0% | −0.2—−7933% | |
| Shares issued | — | — | — | — | — | 0*−100%— | 0*−100%0.0% | 20*—1423% | 8.6−12.2%529% | 4.9*—— | 1.0*—— | −0.1*—−43.6% | 9.7—324567% | |
| Cash from financing activities | 26−18.5%200008% | 4.0*—— | 2.0*—— | −1.2*—−13333% | 21—530025% | 0*−100%— | 0*−100%0.0% | 21*—1509% | 11+14.3%690% | 4.9*—— | 1.0*—— | −0.1*—−42.8% | 9.7—324633% | |
| Exchange-rate effect on cash | 0.0—200% | 0.1*—— | 0.0*—— | −0.0*—−55.6% | −0.0—−900% | — | — | — | — | — | — | — | — | |
| Change in cash | 2.5−84.9%19138% | 2.8*—— | −5.0*—— | −9.8*—−108511% | 14—360600% | −3.6*−373%— | −2.9*—−1141% | 15*—1076% | 8.1+354%504% | 1.3*—— | −4.4*—— | −5.9*—−2376% | 1.8—59767% | |
| Report | Worked out | 10-K | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Dec 31, 2023. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
Events at Advaxis Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.
Delisting notice 1 · Auditor changed 1 · Acquisition or sale completed 3 · Directors and officers 7 · Material agreement 6 · New debt 1 · Unregistered share sale 5 · Shareholder rights changed 1 · Bylaws or fiscal year changed 4 · Shareholder vote 5
| Filed | What happened | Filing |
|---|---|---|
| Directors and officers | 8-K | |
| Acquisition or sale completedUnregistered share sale | 8-K | |
| Material agreementNew debt | 8-K | |
| Directors and officers | 8-K | |
| Unregistered share saleShareholder vote | 8-K | |
| Directors and officersMaterial agreement | 8-K | |
| Acquisition or sale completedDirectors and officersUnregistered share sale | 8-K | |
| Material agreementUnregistered share sale | 8-K | |
| Material agreementShareholder vote | 8-K | |
| Auditor changed | 8-K | |
| Bylaws or fiscal year changed | 8-K | |
| Acquisition or sale completedDirectors and officersBylaws or fiscal year changed | 8-K | |
| Shareholder vote | 8-K | |
| Material agreementUnregistered share saleShareholder rights changedBylaws or fiscal year changed | 8-K | |
| Material agreement | 8-K | |
| Directors and officersShareholder vote | 8-K | |
| Bylaws or fiscal year changed | 8-K | |
| Delisting notice | 8-K | |
| Directors and officers | 8-K | |
| Shareholder vote | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Apr 3, 2024
Acquisitions and funding#
8 private funding rounds before listing
Private share sales · funding history
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Jan 2022 | $5 M | No. 8 | $2 to $10 million | 6 | equity | SEC |
| Apr 2021 | $11 M | No. 7 | $10 to $50 million | 2 | options | SEC |
| May 2012 | $4 M | No. 6 | $2 to $10 million | 29 | equity, options | SEC |
| Jan 2012 | $1 M | No. 5 | Under $2 million | 12 | debt, options | SEC |
| Oct 2011 | $2 M | No. 4 | Under $2 million | 12 | debt, options | SEC |
| May 2011 | $6 M | No. 3 | $2 to $10 million | 24 | debt, options | SEC |
| Jul 2010 | $8 M | No. 2 | $2 to $10 million | 1 | equity, options | SEC |
| Sep 2009 | $5 M | No. 1 | $2 to $10 million | 1 | options | SEC |
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
How Advaxis Inc. compares in Biotechnology
- Revenue$0 M · higher than 13% of 647
- Revenue growth-98.5% · higher than 1% of 438
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Advaxis Inc.🇺🇸 | $6 M | — | — | -98.5% |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Novo Nordisk A/S$203.2 B
- Vertex Pharmaceuticals Incorporated$134.3 B
- Moderna, Inc.$90.1 B
- Regeneron Pharmaceuticals, Inc.$84.1 B
- Argenx SE$52.8 B
- CSL Limited$51.6 B
Sources and freshness
- Market cap:
- Jul 30, 2023 (last known)
- Annual results:
- For year ending December-2023
- Balance sheet:
- As of December-2023
- Profile updated:
- Nov 16, 2026
Figures from SEC filing, Wikidata, value.today research, Wikipedia, Wikimedia Commons; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Advaxis Inc.? Verify and update this profile — free
Show Advaxis Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.